Dynarrestin is a novel inhibitor of cytoplasmic Dyneins 1 and 2, acts reversibly to inhibit cytoplasmic dynein 1-dependent microtubule binding and motility in vitro without affecting ATP hydrolysis.

Dynein2-IN-37 (Ciliobrevin analog 37) is a potent, selective cytoplasmic dynein 2 ATPase activity antagonist with IC50 of 11 uM, shows weak inhibition for dynein 2 (IC50=280 uM).

Dynole 34-2 is a potent dynamin GTPase inhibitor with IC50 of 6.9 and 14.2 uM for full-length dynI and dynII GTPase activity, respectively.

DZ-2384 (DZ2384) is a microtubule-targeting agent, exhibits potent antitumor activity in models of multiple cancer types.

E 6201 (E6201) is a potent, selective, dual MEK1 and MEKK1 inhibitor, inhibits LPS-induced TNFα transcription with IC50 of 50 nM.

E 6446 is a novel orally available small molecule inhibitor of TLR7 and TLR9 with IC50 of 1.78 uM and 0.01 uM, respectively.

E1231 (E-1231) is a small molecule SIRT1 activator with EC50 of 0.83 uM, interactes with recombinant human SIRT1 protein and deacetylated liver X receptor-alpha (LXRα).

E3 Ligand-Linker Conjugate 1 is an E3 ligand- Linker Conjugate for PROTAC.

E3 Ligand-Linker Conjugate 5 is an E3 ligase ligand-linker conjugate for PROTAC..

E3 ligase Ligand 1 dihydrochloride is a Hippel-Landau (VHL) E3 ligase-binding moiety based on PROTAC technology.

E3 ligase Ligand 2 is a Ligand for E3 Ligase used in PROTAC technology.

E3 Ligase Ligand-Linker Conjugates 23 (TFA) is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.

E3 Ligase Ligand-Linker Conjugates 25 Trifluoroacetate is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.

E-3810 is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity.

E-4031 is a benzenesulfonamide antiarrhythmic agent; blocks the ATP-sensitive potassium channel.

E5555 shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC values of 0.064 and 0.031 μM respectively.

E-5842 is a preferential sigma-1 receptor ligand, demonstrates potential atypical antipsychotic effects in vivo.

E-5842 is a preferential sigma-1 receptor ligand, demonstrates potential atypical antipsychotic effects in vivo.

E-64 is a natural, potent, and irreversible inhibitor of cysteine proteases; IC50 values for inhibiting cathepsins K, S, and L, in vitro, are 1.4, 4.1, and 2.5 nM, respectively.

E64FC26 is a highly potent pan-style inhibitor of Protein Disulfide Isomerase (PDI) with IC50 of 1.9 uM (PDIA1), also inhibits all other members of the PDI family, including PDIA3, PDIA4, TXNDC5, and PDIA6.

E67-2 is a potent and selective inhibitor of H3K9 Jumonji demethylase KIAA1718 (KDM7A) with IC50 of 3.4 uM.

E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities.